Proactive Investors - Run By Investors For Investors

ImmuPharma says last patient dosed in Phase III clinical trial of lupus treatment, Lupuzor™

ImmuPharma’s chairman, Tim McCarthy, said: "Importantly we continue to see robust safety and we look forward with continued confidence to reporting top line results of the study in Q1 2018"
Drug trials
The specialist drug discovery and development company said 200 patients have been successfully recruited and dosed

ImmuPharma PLC (LON:IMM) has confirmed that the last patient has completed dosing within the 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.

The specialist drug discovery and development company said 200 patients have been successfully recruited and dosed, with top line results remaining on track to be reported in the first quarter of 2018.

WATCH: Immupharma 'looking forward and planning for success' with Lupuzor

Commenting on the trial update, ImmuPharma’s chairman, Tim McCarthy, said: "We are delighted to announce this significant milestone that all patients have now completed dosing in this pivotal Phase III trial for Lupuzor™.”

READ: ImmuPharma banks extra £600,000 from Lanstead agreement

He added: “Importantly we continue to see robust safety and we look forward with continued confidence to reporting top line results of the study in Q1 2018."

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
man coughing
November 09 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them
bacteria
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use